Patent “March-In” As Price Control Draw Little Support At US National Academies Meeting

 
• By Cole Werble

The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.

Birch Bayh meeting with Bob Dole | Robert and Elizabeth Dole Archive and Special Collections
March-in rights are based on 1980 legislation authored by Sens. Birch Bayh (r) and Robert Dole (l). • Source: Robert J. Dole Archive and Special Collections, The University of Kansas

More from Pricing Debate

More from Market Access